March 16, 2004
CHEMNAVIGATOR AND GRIFFITH UNIVERSITY INSTITUTE FOR GLYCOMICS SIGN COLLABORATIVE DISCOVERY AGREEMENT
ChemNavigator today announced it has signed a collaborative research agreement with Griffith University's Institute for Glycomics, based on Australia's Gold Coast, Queensland. Under the terms of the one-year collaboration, ChemNavigator will provide the Institute access to certain ChemMatrix™ products and services including the iResearch™ Library and Chemistry Procurement Service. In exchange, the Institute will provide historical biological screening data as well as biological screening services designed to identify compounds that inhibit the activity of the sialidase enzyme of the bacterium Vibrio cholerae, which is responsible for a severe intestinal disease.
ChemNavigator will use historical screening data along with its proprietary 3DPL™ virtual screening technology to develop and validate in silico screens for sialidase inhibitors. In addition, ChemNavigator will use these 3DPL based in silico screens and the protein structure for V. cholerae sialidase to screen millions of potential sialidase inhibitor compounds contained within the iResearch Library. High scoring compounds will be tested in the Institute for Glycomics biological assay system to confirm inhibition of V. cholerae sialidase. ChemNavigator will retain all rights to biological screening results for this collaboration.
"We are pleased to secure this collaborative discovery agreement with the Institute for Glycomics," said Duncan Beniston, Director of Business Development at ChemNavigator. "This agreement will open up a world of chemistry samples to the Institute's research programs and will provide ChemNavigator valuable biological screening services to both validate 3DPL and identify new potentially valuable V. cholerae sialidase inhibitors."
The Institute for Glycomics will use the iResearch Library and Chemistry Procurement Services as sources of potential drug compounds to be used in various research programs. The Institute will receive regular updates on the iResearch Library throughout the year to ensure its researchers have access to the latest drug-like chemistry sample data from around the world.
"Access to the iResearch Library of available drug-like compounds will allow our scientists to efficiently identify probe molecules we can procure in a timely and cost effective manner" said Institute for Glycomics Executive Director Professor Mark von Itzstein. "Collaborating with ChemNavigator is an example of how our institute seeks to work with other organizations around the world and facilitate biomedical research to improve human life."
About the Institute for Glycomics
The Institute for Glycomics (formerly known as the Centre for Biomolecular Science & Drug Discovery) was established at the Gold Coast campus of Griffith University as a result of an agreement between the Queensland State Government and Griffith University in February 2000. The Executive Director is Professor Mark von Itzstein, an Australia Prize winner for his efforts in the development of the Anti-Influenza Drug Zanamivir sold under the name Relenza™. The Institute is part of Griffith University and has been designed with an intention to contribute to the growing Australian biotechnology industry on the Gold Coast in Queensland. The Institute seeks to improve quality of life during the ageing process (healthy ageing) through the development of an understanding of the roles of carbohydrates in healthy biology and in disease. In this respect, the Institute is pursuing the following outcomes: 1) the advancement of knowledge of fundamental importance to the understanding of the roles played by carbohydrates and other biomolecules in biological systems; 2) the design and synthesis of potential drug candidates and generic technology, which in the longer term will contribute to national productivity; 3) the development of enabling glycotechnologies; 4) the dissemination of this expertise nationally and internationally through the training of highly-skilled postgraduate students and scientist exchange programs.
This agreement expands the portfolio of Professor von Itzstein's research group at the Institute, with a member of the group, Dr Thomas Haselhorst, responsible for the experimental program.
For more information contact:
Karyn Joyner
Business Manager
k.joyner@griffith.edu.au
Ph: +61 7 5552 7033
About ChemNavigator
ChemNavigator is a privately held pharmaceutical research company focused on drug discovery using our proprietary proteomics and cheminformatics technologies, called 3DPL™ and ChemMatrix™. Our competitive advantage is our unique ability to identify and analyze, with unmatched speed, the biochemical relationships that exist between a potential drug compound and its entire drug target molecule. Our 3-DPL technology is designed to allow more efficient and cost effective drug discovery by providing the ability to screen tens of millions of potential drugs in silico in order to rapidly identify compounds with a high likelihood of showing favorable activity. Our ChemMatrix technology is employed within products and services used by over 40 pharmaceutical and biotechnology companies.
For more information contact:
Scott Hutton, President & CEO
here
ChemNavigator today announced it has signed a collaborative research agreement with Griffith University's Institute for Glycomics, based on Australia's Gold Coast, Queensland. Under the terms of the one-year collaboration, ChemNavigator will provide the Institute access to certain ChemMatrix™ products and services including the iResearch™ Library and Chemistry Procurement Service. In exchange, the Institute will provide historical biological screening data as well as biological screening services designed to identify compounds that inhibit the activity of the sialidase enzyme of the bacterium Vibrio cholerae, which is responsible for a severe intestinal disease.
ChemNavigator will use historical screening data along with its proprietary 3DPL™ virtual screening technology to develop and validate in silico screens for sialidase inhibitors. In addition, ChemNavigator will use these 3DPL based in silico screens and the protein structure for V. cholerae sialidase to screen millions of potential sialidase inhibitor compounds contained within the iResearch Library. High scoring compounds will be tested in the Institute for Glycomics biological assay system to confirm inhibition of V. cholerae sialidase. ChemNavigator will retain all rights to biological screening results for this collaboration.
"We are pleased to secure this collaborative discovery agreement with the Institute for Glycomics," said Duncan Beniston, Director of Business Development at ChemNavigator. "This agreement will open up a world of chemistry samples to the Institute's research programs and will provide ChemNavigator valuable biological screening services to both validate 3DPL and identify new potentially valuable V. cholerae sialidase inhibitors."
The Institute for Glycomics will use the iResearch Library and Chemistry Procurement Services as sources of potential drug compounds to be used in various research programs. The Institute will receive regular updates on the iResearch Library throughout the year to ensure its researchers have access to the latest drug-like chemistry sample data from around the world.
"Access to the iResearch Library of available drug-like compounds will allow our scientists to efficiently identify probe molecules we can procure in a timely and cost effective manner" said Institute for Glycomics Executive Director Professor Mark von Itzstein. "Collaborating with ChemNavigator is an example of how our institute seeks to work with other organizations around the world and facilitate biomedical research to improve human life."
About the Institute for Glycomics
The Institute for Glycomics (formerly known as the Centre for Biomolecular Science & Drug Discovery) was established at the Gold Coast campus of Griffith University as a result of an agreement between the Queensland State Government and Griffith University in February 2000. The Executive Director is Professor Mark von Itzstein, an Australia Prize winner for his efforts in the development of the Anti-Influenza Drug Zanamivir sold under the name Relenza™. The Institute is part of Griffith University and has been designed with an intention to contribute to the growing Australian biotechnology industry on the Gold Coast in Queensland. The Institute seeks to improve quality of life during the ageing process (healthy ageing) through the development of an understanding of the roles of carbohydrates in healthy biology and in disease. In this respect, the Institute is pursuing the following outcomes: 1) the advancement of knowledge of fundamental importance to the understanding of the roles played by carbohydrates and other biomolecules in biological systems; 2) the design and synthesis of potential drug candidates and generic technology, which in the longer term will contribute to national productivity; 3) the development of enabling glycotechnologies; 4) the dissemination of this expertise nationally and internationally through the training of highly-skilled postgraduate students and scientist exchange programs.
This agreement expands the portfolio of Professor von Itzstein's research group at the Institute, with a member of the group, Dr Thomas Haselhorst, responsible for the experimental program.
For more information contact:
Karyn Joyner
Business Manager
k.joyner@griffith.edu.au
Ph: +61 7 5552 7033
About ChemNavigator
ChemNavigator is a privately held pharmaceutical research company focused on drug discovery using our proprietary proteomics and cheminformatics technologies, called 3DPL™ and ChemMatrix™. Our competitive advantage is our unique ability to identify and analyze, with unmatched speed, the biochemical relationships that exist between a potential drug compound and its entire drug target molecule. Our 3-DPL technology is designed to allow more efficient and cost effective drug discovery by providing the ability to screen tens of millions of potential drugs in silico in order to rapidly identify compounds with a high likelihood of showing favorable activity. Our ChemMatrix technology is employed within products and services used by over 40 pharmaceutical and biotechnology companies.
For more information contact:
Scott Hutton, President & CEO
here
©1999-2010 ChemNavigator.com, Inc. All rights reserved.